ArticleDiscover nano2026
A bibliometric analysis of the evolution of nanotechnology research in precision theranostics for nasopharyngeal carcinoma.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to analyze the global research landscape, collaborative patterns, and developmental trends of nanotechnology applications in nasopharyngeal carcinoma (NPC) using bibliometric analysis and knowledge visualization techniques.
methodsPublications from 1985 to 2024 were retrieved from the Web of Science Core Collection database. A bibliometric analysis was conducted using the R-package bibliometrix (version 4.5.0) to evaluate publication metrics, while knowledge graph visualization was performed using CiteSpace software (version 6.2.6) to identify research clusters, evolutionary pathways, and emerging topics.
resultsWe identified 321 relevant publications, demonstrating exponential growth (14.85/year, R
conclusionNanotechnology in NPC is rapidly evolving toward integrated theranostic platforms; however, clinical translation requires addressing scale-up manufacturing and long-term safety assessment challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.